Logo image of ONTX

ONCONOVA THERAPEUTICS INC (ONTX) Stock Fundamental Analysis

NASDAQ:ONTX - Nasdaq - US68232V8019 - Common Stock - Currency: USD

0.9953  0 (-0.47%)

After market: 0.9012 -0.09 (-9.45%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ONTX. ONTX was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of ONTX is average, but there are quite some concerns on its profitability. ONTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ONTX had negative earnings in the past year.
In the past year ONTX has reported a negative cash flow from operations.
In the past 5 years ONTX always reported negative net income.
In the past 5 years ONTX always reported negative operating cash flow.
ONTX Yearly Net Income VS EBIT VS OCF VS FCFONTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

ONTX's Return On Assets of -74.67% is on the low side compared to the rest of the industry. ONTX is outperformed by 69.85% of its industry peers.
With a Return On Equity value of -139.07%, ONTX is not doing good in the industry: 67.34% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -74.67%
ROE -139.07%
ROIC N/A
ROA(3y)-67.68%
ROA(5y)-81.73%
ROE(3y)-169.29%
ROE(5y)-214.83%
ROIC(3y)N/A
ROIC(5y)N/A
ONTX Yearly ROA, ROE, ROICONTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400

1.3 Margins

ONTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONTX Yearly Profit, Operating, Gross MarginsONTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

ONTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ONTX remains at a similar level compared to 1 year ago.
There is no outstanding debt for ONTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ONTX Yearly Shares OutstandingONTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
ONTX Yearly Total Debt VS Total AssetsONTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

ONTX has an Altman-Z score of -25.63. This is a bad value and indicates that ONTX is not financially healthy and even has some risk of bankruptcy.
ONTX has a worse Altman-Z score (-25.63) than 86.93% of its industry peers.
ONTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.63
ROIC/WACCN/A
WACC9.2%
ONTX Yearly LT Debt VS Equity VS FCFONTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

ONTX has a Current Ratio of 2.79. This indicates that ONTX is financially healthy and has no problem in meeting its short term obligations.
ONTX has a Current ratio (2.79) which is comparable to the rest of the industry.
A Quick Ratio of 2.79 indicates that ONTX has no problem at all paying its short term obligations.
ONTX has a Quick ratio (2.79) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.79
ONTX Yearly Current Assets VS Current LiabilitesONTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

ONTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.25%.
ONTX shows a decrease in Revenue. In the last year, the revenue decreased by -1.25%.
The Revenue for ONTX have been decreasing by -21.87% on average. This is quite bad
EPS 1Y (TTM)-21.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.54%
Revenue 1Y (TTM)-1.25%
Revenue growth 3Y-52.75%
Revenue growth 5Y-21.87%
Sales Q2Q%-5%

3.2 Future

ONTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.43% yearly.
ONTX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.62% yearly.
EPS Next Y-7.23%
EPS Next 2Y0.68%
EPS Next 3Y1.19%
EPS Next 5Y1.43%
Revenue Next Year2.54%
Revenue Next 2Y11.27%
Revenue Next 3Y12.62%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ONTX Yearly Revenue VS EstimatesONTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
ONTX Yearly EPS VS EstimatesONTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2K -4K -6K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ONTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONTX Price Earnings VS Forward Price EarningsONTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONTX Per share dataONTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.68%
EPS Next 3Y1.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ONTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCONOVA THERAPEUTICS INC

NASDAQ:ONTX (4/2/2024, 8:00:02 PM)

After market: 0.9012 -0.09 (-9.45%)

0.9953

0 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-07 2024-03-07/amc
Earnings (Next)05-13 2024-05-13/amc
Inst Owners0.01%
Inst Owner Change0%
Ins Owners53.53%
Ins Owner Change0%
Market Cap20.90M
Analysts84.44
Price Target8.5 (754.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.75%
Min EPS beat(2)22.24%
Max EPS beat(2)37.25%
EPS beat(4)4
Avg EPS beat(4)19.05%
Min EPS beat(4)7.73%
Max EPS beat(4)37.25%
EPS beat(8)6
Avg EPS beat(8)13.03%
EPS beat(12)10
Avg EPS beat(12)16.33%
EPS beat(16)12
Avg EPS beat(16)10.3%
Revenue beat(2)0
Avg Revenue beat(2)-17.18%
Min Revenue beat(2)-19.3%
Max Revenue beat(2)-15.06%
Revenue beat(4)1
Avg Revenue beat(4)-16.71%
Min Revenue beat(4)-33.91%
Max Revenue beat(4)1.42%
Revenue beat(8)3
Avg Revenue beat(8)-11.8%
Revenue beat(12)6
Avg Revenue beat(12)12.92%
Revenue beat(16)6
Avg Revenue beat(16)-10.23%
PT rev (1m)0%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.57%
EPS NY rev (1m)0%
EPS NY rev (3m)0.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 88.19
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS0.01
BVpS0.69
TBVpS0.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.67%
ROE -139.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-67.68%
ROA(5y)-81.73%
ROE(3y)-169.29%
ROE(5y)-214.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.79
Altman-Z -25.63
F-Score3
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.54%
EPS Next Y-7.23%
EPS Next 2Y0.68%
EPS Next 3Y1.19%
EPS Next 5Y1.43%
Revenue 1Y (TTM)-1.25%
Revenue growth 3Y-52.75%
Revenue growth 5Y-21.87%
Sales Q2Q%-5%
Revenue Next Year2.54%
Revenue Next 2Y11.27%
Revenue Next 3Y12.62%
Revenue Next 5YN/A
EBIT growth 1Y-22.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.78%
EBIT Next 3Y-13.83%
EBIT Next 5YN/A
FCF growth 1Y15.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.99%
OCF growth 3YN/A
OCF growth 5YN/A